|
SDHC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.35119999966626E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.01100000049881E-07 |
| Normal-vs-Stage2 |
2.366800E-01 |
| Normal-vs-Stage3 |
1.54194999999469E-05 |
| Normal-vs-Stage4 |
5.07780000047475E-07 |
| Stage1-vs-Stage2 |
1.282000E-02 |
| Stage1-vs-Stage3 |
9.509400E-01 |
| Stage1-vs-Stage4 |
2.388600E-01 |
| Stage2-vs-Stage3 |
2.087500E-02 |
| Stage2-vs-Stage4 |
3.524700E-03 |
| Stage3-vs-Stage4 |
3.099400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.06719999948268E-07 |
| Normal-vs-AfricanAmerican |
1.621950E-02 |
| Normal-vs-Asian |
1.11289999993325E-07 |
| Caucasian-vs-AfricanAmerican |
2.870800E-01 |
| Caucasian-vs-Asian |
1.552230E-01 |
| AfricanAmerican-vs-Asian |
3.215900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.68299999994781E-06 |
| Normal-vs-Female |
2.07699999998923E-06 |
| Male-vs-Female |
6.774600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.68430000449627E-08 |
| Normal-vs-Age(41-60Yrs) |
3.27650000020441E-07 |
| Normal-vs-Age(61-80Yrs) |
1.361730E-02 |
| Normal-vs-Age(81-100Yrs) |
1.025770E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.487000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.956410E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.401600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.058300E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.214400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.898000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.592050E-01 |
| Classical-VS-Follicular |
8.239200E-03 |
| Classical-VS-Other |
6.906600E-01 |
| Classical-VS-Normal |
2.73519999982597E-07 |
| Tall-VS-Follicular |
1.302390E-03 |
| Tall-VS-Other |
9.456600E-01 |
| Tall-VS-Normal |
3.18020000333874E-08 |
| Follicular-VS-Other |
2.533000E-01 |
| Follicular-VS-Normal |
4.504300E-02 |
| Other-VS-Normal |
7.863200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.55346999999306E-05 |
| Normal-vs-N1 |
5.87219994852006E-09 |
| N0-vs-N1 |
5.338800E-03 |
|
|
